Author: Edward Shorter
Publisher: Oxford University Press
ISBN: 0199709335
Category : Medical
Languages : en
Pages : 321
Get Book Here
Book Description
Psychiatry today is a barren tundra, writes medical historian Edward Shorter, where drugs that don't work are used to treat diseases that don't exist. In this provocative volume, Shorter illuminates this dismal landscape, in a revealing account of why psychiatry is "losing ground" in the struggle to treat depression. Naturally, the book looks at such culprits as the pharmaceutical industry, which is not inclined to market drugs once the patent expires, leading to the endless introduction of new--but not necessarily better--drugs. But the heart of the book focuses on an unexpected villain: the FDA, the very agency charged with ensuring drug safety and effectiveness. Shorter describes how the FDA permits companies to test new products only against placebo. If you can beat sugar pills, you get your drug licensed, whether or not it is actually better than (or even as good as) current medications, thus sweeping from the shelves drugs that may be superior but have lost patent protection. The book also examines the FDA's early power struggles against the drug industry, an influence-grab that had little to do with science, and which left barbiturates, opiates, and amphetamines all underprescribed, despite the fact that under careful supervision they are better at treating depression, with fewer side effects, than the newer drugs in the Prozac family. Shorter also castigates academia, showing how two forms of depression, melancholia and nonmelancholia--"as different from each other as chalk and cheese"--became squeezed into one dubious classification, major depression, which was essentially a political artifact born of academic infighting. An astonishing and troubling look at modern psychiatry, Losing Ground is a book that is sure to spark controversy for years to come.
Author: Charles D. Ciccone
Publisher: F.A. Davis
ISBN: 0803640048
Category : Medical
Languages : en
Pages : 1217
Get Book Here
Book Description
A one-of-a-kind guide specifically for rehabilitation specialists! A leader in pharmacology and rehabilitation, Charles Ciccone, PT, PhD offers a concise, easy-to-access resource that delivers the drug information rehabilitation specialists need to know. Organized alphabetically by generic name, over 800 drug monographs offer the most up-to-date information on drug indications, therapeutic effects, potential adverse reactions, and much more! A list of implications for physical therapy at the end of each monograph helps you provide the best possible care for your patients. It’s the perfect companion to Pharmacology in Rehabilitation, 4th Edition!
Author: Edward Shorter
Publisher: Oxford University Press
ISBN: 0195368746
Category : Medical
Languages : en
Pages : 321
Get Book Here
Book Description
In this volume, Shorter presents a revealing account of why psychiatry is 'losing ground' in the struggle to treat depression. It focuses on an unexpected villain - the FDA, the very agency charged with ensuring drug safety and effectiveness. Shorter describes how the FDA permits companies to test new products only against placebo.
Author: Shoshana Bennett
Publisher: Rowman & Littlefield
ISBN: 076275365X
Category : Psychology
Languages : en
Pages : 267
Get Book Here
Book Description
Antidepressants today top the list of drugs prescribed to women. But what happens when you add pregnancy into the mix? Pregnant on Prozacis the first guide to separate the myths from the facts. Taking a pull-no-punches, prescriptive approach, it clearly spells out not only the possible risks of antidepressant use—whether it be Prozac, Wellbutrin, or any of the host of other drugs—by hopeful mothers but also the lesser-known yet serious risks to both fetus and mother from untreated depression. Shoshana Bennett answers such questions as: Does the media exaggerate the risk? What of options such as tapering the dose? What alternatives are worth pursuing? Most importantly, she empowers each woman with the knowledge to make the best decision for her. Pregnant on Prozac is a must-have for any prospective mother who has experienced depression or anxiety as well as anyone with a friend or loved one in this situation.
Author: Joseph Glenmullen
Publisher: Simon and Schuster
ISBN: 0743200624
Category : Family & Relationships
Languages : en
Pages : 388
Get Book Here
Book Description
In a controversial look at the potent drugs millions of Americans consume each day--for everything from anxiety to sexual addiction--Dr. Glenmullen presents authoritative information on why they are risky and provides advice on choosing safer alternative treatments.
Author: Lauren Slater
Publisher: Random House
ISBN: 0679462791
Category : Biography & Autobiography
Languages : en
Pages : 155
Get Book Here
Book Description
The author of the acclaimed Welcome to My Country describes in this provocative and funny memoir the ups and downs of living on Prozac for ten years, and the strange adjustments she had to make to living "normal life." Today millions of people take Prozac, but Lauren Slater was one of the first. In this rich and beautifully written memoir, she describes what it's like to spend most of your life feeling crazy--and then to wake up one day and find yourself in the strange state of feeling well. And then to face the challenge of creating a whole new life. Once inhibited, Slater becomes spontaneous. Once terrified of maintaining a job, she accepts a teaching position and ultimately earns several degrees in psychology. Once lonely, she finds love with a man who adores her. Slater is wonderfully thoughtful and articulate about all of these changes, and also about the downside of taking Prozac: such matters as dependency, sexual dysfunction, and Prozac "poop-out." "The beauty of Lauren Slater's prose is shocking," said Newsday about Welcome to My Country, and Slater's remarkable gifts as a writer are present here in sentences that are like elegant darts, hitting at the center of the deepest human feelings. Prozac Diary is a wonderfully written report from inside a decade on Prozac, and an original writer's acute observations on the challenges of living modern life.
Author: Peter D. Kramer
Publisher: Penguin
ISBN: 0140266712
Category : Psychology
Languages : en
Pages : 481
Get Book Here
Book Description
The New York Times bestselling examination of the revolutionary antidepressant, with a new introduction and afterword reflecting on Prozac’s legacy and the latest medical research “Peter Kramer is an analyst of exceptional sensitivity and insight. To read his prose on virtually any subject is to be provoked, enthralled, illuminated.” —Joyce Carol Oates When antidepressants like Prozac first became available, Peter D. Kramer prescribed them, only to hear patients say that on medication, they felt different—less ill at ease, more like the person they had always imagined themselves to be. Referencing disciplines from cellular biology to animal ethology, Dr. Kramer worked to explain these reports. The result was Listening to Prozac, a revolutionary book that offered new perspectives on antidepressants, mood disorders, and our understanding of the self—and that became an instant national and international bestseller. In this thirtieth anniversary edition, Dr. Kramer looks back at the influence of his groundbreaking book, traces progress in the relevant sciences, follows trends in the use and public understanding of antidepressants, and assesses potential breakthroughs in the treatment of depression. The new introduction and afterword reinforce and reinvigorate a book that the New York Times called “originally insightful” and “intelligent and informative,” a window on a medicine that is “telling us new things about the chemistry of human character.”
Author: Graziano Pinna
Publisher:
ISBN: 9781634820769
Category :
Languages : en
Pages : 412
Get Book Here
Book Description
Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.
Author: Richard M. Berlin
Publisher: Johns Hopkins University Press+ORM
ISBN: 0801895294
Category : Literary Criticism
Languages : en
Pages : 201
Get Book Here
Book Description
In this collection of 16 essays, poets discuss psychiatric treatment and their work. Poets on Prozac shatters the notion that madness fuels creativity by giving voice to contemporary poets who have battled myriad psychiatric disorders, including depression, schizophrenia, post-traumatic stress disorder, and substance abuse. The sixteen essays collected here address many provocative questions: Does emotional distress inspire great work? Is artistry enhanced or diminished by mental illness? What effect does substance abuse have on esthetic vision? Do psychoactive medications impinge on ingenuity? Can treatment enhance inherent talents, or does relieving emotional pain shut off the creative process? Featuring examples of each contributor’s poetry before, during, and after treatment, this original and thoughtful collection finally puts to rest the idea that a tortured soul is one’s finest muse. Honorable Mention, 2008 PROSE Award for Best Book in Psychology. “A fascinating collection of 16 essays, as insightful as they are compulsively readable. Each is honest and sharply written, covering a range of issues (depression, anxiety, obsessive-compulsive disorder, psychosis, substance abuse or, in acutely deadpan Andrew Hudgins’s case, “tics, twitches, allergies, tooth-grinding, acid reflux, migraines . . . and shingles”) along with treatment methods, incorporating personal anecdotes and excerpts from poems and journals. . . . Anyone affected by mental illness or intrigued by the question of its role in the arts should find this volume absorbing.” —Publishers Weekly “Berlin has done a marvelous job of showing us how ordinary poets are; the selected poets have shown us that mental illness shares with other experiences a capacity to reveal our humanity.” —Metapsychology
Author: Jonathan Metzl
Publisher: Duke University Press
ISBN: 0822386704
Category : Medical
Languages : en
Pages : 295
Get Book Here
Book Description
Pills replaced the couch; neuroscience took the place of talk therapy; and as psychoanalysis faded from the scene, so did the castrating mothers and hysteric spinsters of Freudian theory. Or so the story goes. In Prozac on the Couch, psychiatrist Jonathan Michel Metzl boldly challenges recent psychiatric history, showing that there’s a lot of Dr. Freud encapsulated in late-twentieth-century psychotropic medications. Providing a cultural history of treatments for depression, anxiety, and other mental illnesses through a look at the professional and popular reception of three “wonder drugs”—Miltown, Valium, and Prozac—Metzl explains the surprising ways Freudian gender categories and popular gender roles have shaped understandings of these drugs. Prozac on the Couch traces the notion of “pills for everyday worries” from the 1950s to the early twenty-first century, through psychiatric and medical journals, popular magazine articles, pharmaceutical advertisements, and popular autobiographical "Prozac narratives.” Metzl shows how clinical and popular talk about these medications often reproduces all the cultural and social baggage associated with psychoanalytic paradigms—whether in a 1956 Cosmopolitan article about research into tranquilizers to “cure” frigid women; a 1970s American Journal of Psychiatry ad introducing Jan, a lesbian who “needs” Valium to find a man; or Peter Kramer’s description of how his patient “Mrs. Prozac” meets her husband after beginning treatment. Prozac on the Couch locates the origins of psychiatry’s “biological revolution” not in the Valiumania of the 1970s but in American popular culture of the 1950s. It was in the 1950s, Metzl points out, that traditional psychoanalysis had the most sway over the American imagination. As the number of Miltown prescriptions soared (reaching 35 million, or nearly one per second, in 1957), advertisements featuring uncertain brides and unfaithful wives miraculously cured by the “new” psychiatric medicines filled popular magazines. Metzl writes without nostalgia for the bygone days of Freudian psychoanalysis and without contempt for psychotropic drugs, which he himself regularly prescribes to his patients. What he urges is an increased self-awareness within the psychiatric community of the ways that Freudian ideas about gender are entangled in Prozac and each new generation of wonder drugs. He encourages, too, an understanding of how ideas about psychotropic medications have suffused popular culture and profoundly altered the relationship between doctors and patients.
